Skip to main content

Table 1 Patient characteristics a

From: Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody–negative arthralgia patients at risk for rheumatoid arthritis

Characteristics

Symptom-free controls

ACPA-negative arthralgia

ACPA-negative RA

(n = 19)

(n = 64)

(n = 20)

Mean age, yr (SD)

46.2 (11.8)

41.9 (14.3)

58.7 (14.5)

Females, n (%)

15 (78.9)

46 (71.9)

11 (55.0)

Positive family history of RA, n (%)

N/A

25 (39.1)

4 (20.0)

Median symptom duration at time of inclusion, wk (IQR)

N/A

13.4 (8.4 to 26.4)

17.6 (11.5 to 25.9)

Gradual symptom onset, n (%)

N/A

48 (75.0)

12 (60.0)

Initial symptom localization, n (%)

N/A

  

   Upper extremities, n (%)

 

47 (73.4)

10 (50.0)

   Lower extremities, n (%)

 

2 (3.1)

4 (20.0)

   Upper and lower extremities, n (%)

 

15 (23.4)

6 (30.0)

Symmetrical localization, n (%)

N/A

46 (71.9)

13 (65.0)

Median morning stiffness, min (IQR)

N/A

45 (15 to 90)

120 (30 to 120)

Median tender joint count in 68 joints (IQR)

0

5.5 (3 to 10.8)

12 (4.8 to 17.8)

Median swollen joint count 66 joints (IQR)

0

0

6 (4 to 11)

ACPA positivity (>7.0 IU/ml), n (%)

N/A

0

0

IgM RF positivity (>3.5 IU/ml), n (%)

N/A

9 (14.1)

3 (15.0)

Increased CRP level (>10 mg/L), n (%)

N/A

10 (15.6)

11 (55.0)

  1. aACPA, Anticitrullinated peptide antibody; CRP, C-reactive protein; IQR, Interquartile range; IgM RF, Immunoglobulin M rheumatoid factor; N/A, Not applicable; RA, Rheumatoid arthritis; SD, Standard deviation.